BBIO News and Press, BridgeBio Pharma Inc. From 02/09/26

2026-02-09 01:10:13 ET Initiating BridgeBio with a neutral rating I initiate coverage of Bridge Bio ( BBIO ) with a neutral rating, which reflects the balance between tangible de-risking following the US approval/early commercialization of acoramidis (Attruby) in the transthyret...

PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows: BridgeBio Pharma, Inc. (Nasdaq: BBI...

2026-01-16 05:03:45 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Bri...

The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturity Offering priced at 0.75% interest rate and 45% conversion premium PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the &#x...

2026-01-14 16:09:21 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Bri...

-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity PALO ALTO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “...

2026-01-12 14:25:58 ET BridgeBio Pharma, Inc. (BBIO) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Co...

2026-01-12 12:34:30 ET More on markets AllianceBernstein sees steady growth in 2026, but flags rising volatility and policy risks Cantor Fitzgerald sees tailwinds for 2026, but warns of a potential Q1 drawdown Goldman Sachs sees the bull market rolling on in 2026 a...

-  Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions writ...

2026-01-09 11:25:07 ET BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study January 9, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Di...